What kind of kidney injury does Zanubrutinib cause?

Prerenal / Hemodynamic AKI — Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome. Other reported patterns: Electrolyte Disturbance, Crystal / Obstructive Nephropathy.

How should kidney function be monitored during Zanubrutinib therapy?

Tumor-lysis labs during early cytoreduction of bulky disease; Blood pressure and rhythm assessment periodically (lowest CV risk of class but still monitored).

How can kidney injury from Zanubrutinib be prevented?

TLS risk stratification with hydration and urate-lowering therapy Blood-pressure monitoring (lower but non-zero risk)

Who is at higher risk of kidney injury from Zanubrutinib?

High tumor burden / bulky disease; Volume depletion; Pre-existing CKD.

Back to explorer

Printable monograph

BTK inhibitor

Zanubrutinib

Brukinsa · Zanu

BTK inhibitor · approved 2019 · 7 citations

Recent· through 2024

Fairly sourced4/9 · 4 signals

Met: 7 citations
Not met: 12+ references
Not met: Accrued over 10+ years (span: 6y)
Met: Beyond single case reports
Not met: Peer-reviewed sources
Met: Landmark reference
Met: Current through 2024
Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A highly selective BTK inhibitor with the lowest cardiovascular signal of the class; tumor lysis is its main renal concern.

MildBTK inhibitor (2nd generation)

CLL/SLLMantle-cell lymphomaMarginal-zone lymphomaWaldenström macroglobulinemiaFollicular lymphoma

§01

Signature kidney injury

Signature lesion

Prerenal / Hemodynamic AKI

Direct nephrotoxicity is not a prominent signal. Cardiovascular toxicity (atrial fibrillation, hypertension) is lower than ibrutinib in pooled and head-to-head (ASPEN, ALPINE) analyses. Tumor lysis can occur with rapid cytoreduction of bulky CLL/lymphoma; renal events are case-level and not well quantified.Source: Moslehi et al., Blood Adv 2024 (pooled CV analysis)

Onset & rechallenge

Time to injuryAcute (~1–7 days)

Tumor lysis early (first cycle); otherwise renal function typically stable.

Distilled from: “Tumor lysis early (first cycle); otherwise renal function typically stable.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Prerenal / Hemodynamic AKI#1 · Signaturequalitative — no citable incidence
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Electrolyte DisturbanceSecondaryqualitative — no citable incidence
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Crystal / Obstructive NephropathySecondaryqualitative — no citable incidence
Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

Incidence not quantified

SeverityMild

ReversibilityVariable

Evidence7 citations

Nephron map

Vasculature / Endothelium

Distal Tubule / Collecting Duct

Tubular Lumen

Prerenal / Hemodynamic AKI

Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

§03

Kidney injury

Mechanism of kidney injury

High BTK selectivity limits the off-target endothelial/kinase effects that drive ibrutinib's hypertension, so atrial fibrillation and hypertension rates are the lowest in the class. AKI is predominantly hemodynamic or due to tumor lysis (hyperuricemia/hyperphosphatemia with intratubular crystal/urate injury) when high-burden disease responds.

Clinical presentation

Usually stable renal function; tumor-lysis labs (hyperkalemia, hyperphosphatemia, hyperuricemia, rising creatinine) in high-risk disease. Lower hypertension/atrial fibrillation than ibrutinib.

Management

Manage tumor lysis with hydration and rasburicase/allopurinol and electrolyte correction; supportive care. Dose-modify (from 160 mg twice daily or 320 mg once daily) for severe toxicity.Lesion-level management framework

Risk factors

High tumor burden / bulky disease
Volume depletion
Pre-existing CKD

Prevention

TLS risk stratification with hydration and urate-lowering therapy
Blood-pressure monitoring (lower but non-zero risk)

Anticancer mechanism· how it treats cancer

Next-generation, highly selective covalent BTK inhibitor designed for complete and sustained BTK occupancy with minimal off-target kinase activity, used in CLL/SLL, mantle-cell lymphoma, marginal-zone lymphoma, Waldenström macroglobulinemia and follicular lymphoma.

Note · Renal toxicity is largely a tumor-lysis phenomenon rather than a direct drug effect; zanubrutinib has the most favorable cardiovascular tolerability of the BTK-inhibitor class.

§04

Clinical depth

Renal dose adjustment

No dose adjustment for mild-to-moderate renal impairment; in severe renal impairment and on dialysis, exposure changes are modest and no dose adjustment is generally required, though data are limited. Hepatic impairment, not renal, drives reduction; minimal renal excretion of unchanged drug.

Dialyzability & ESKD dosing

Not meaningfully dialyzable — highly protein-bound, hepatically (CYP3A) cleared small molecule. No supplemental post-HD dose needed.

Differential diagnosis

Distinguish tumor-lysis AKI (urate/phosphate profile, early) from prerenal azotemia and CLL-intrinsic kidney disease. Because cardiovascular and hypertensive effects are lowest in the class, a marked BP rise should prompt a search for other causes.

Monitoring

Tumor-lysis labs during early cytoreduction of bulky disease
Blood pressure and rhythm assessment periodically (lowest CV risk of class but still monitored)

Key trials & series

Moslehi et al., Blood Adv 2024 — pooled CV analysis (10 studies; ASPEN and ALPINE head-to-head) showing lower atrial fibrillation/hypertension vs ibrutinib

Clinical pearls

Zanubrutinib has the lowest atrial-fibrillation and hypertension rates among BTK inhibitors — the renal story is mostly tumor lysis.
Anticipate and prophylax against TLS when debulking high-burden CLL/lymphoma.
Even on dialysis, exposure changes are modest and generally do not require dose adjustment, though data remain limited.

Beyond the kidney — non-renal toxicities· 2 organ systems

Class-level context for the major non-renal toxicities of the BTK inhibitor class.

Cardiac

Cardiomyopathy, QT, ischemia, myocarditis

Atrial fibrillation, ventricular arrhythmia

Vascular

Hypertension, VTE/ATE, bleeding, aneurysm

Bleeding, hypertension

§05

References

7 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.

Evidence accrual

7 references · 2018–2024 · 5 since 2022

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Zanubrutinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Brentuximab vedotin

Adcetris · Antibody-drug conjugate (CD30/MMAE)

Profile

Tumor lysis in lymphoma.

PRELYTEXTAL

Mild#1 · 89% phenotype match

Polatuzumab vedotin

Polivy · Antibody-drug conjugate (CD79b/MMAE)

Profile

Tumor lysis; emerging renal data.

PRELYTEXTAL

Mild#2 · 89% phenotype match

Pirtobrutinib

Jaypirca · Non-covalent BTK inhibitor

Profile

2023 BTK inhibitor; tumor lysis risk.

XTALPRELYTE

Mild#3 · 85% phenotype match

Epcoritamab

Epkinly · Bispecific (CD20×CD3)

Profile

CRS and tumor lysis — emerging.

PRELYTEXTAL

Moderate#4 · 84% phenotype match

Gemtuzumab ozogamicin

Mylotarg · Antibody-drug conjugate (CD33/calicheamicin)

Profile

Tumor lysis and veno-occlusive disease.

PRELYTEXTAL

Moderate#5 · 84% phenotype match

Glofitamab

Columvi · Bispecific (CD20×CD3)

Profile

CRS and tumor lysis — emerging.

PRELYTEXTAL

Moderate#6 · 84% phenotype match

Compare Zanubrutinib with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across BTK inhibitors

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

1AcalabrutinibHTN — HypertensionMild
2Zanubrutinib· this agentPRE — Prerenal / Hemodynamic AKIMild
3PirtobrutinibXTAL — Crystal / Obstructive NephropathyFAERS AKIMild
4IbrutinibHTN — HypertensionModerate

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.